Related Experiment Video

Updated: May 1, 2026

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

951

Role of GAS5 noncoding RNA in mediating the effects of rapamycin and its analogues on mantle cell lymphoma cells

Mirna Mourtada-Maarabouni1, Gwyn T Williams1

  • 1Institute for Science and Technology in Medicine, Huxley Building, Keele University, Keele, United Kingdom.

Clinical Lymphoma, Myeloma & Leukemia
|April 8, 2014
PubMed
Abstract

Insights

Inhibiting the mTOR pathway shows promise for mantle cell lymphoma (MCL) treatment. Suppressing GAS5 RNA significantly reduced the effectiveness of rapalogue drugs in MCL cells.

Area of Science:

  • Oncology
  • Molecular Biology
  • RNA Therapeutics

Background:

  • The mammalian target of rapamycin (mTOR) pathway is a key therapeutic target for mantle cell lymphoma (MCL).
  • Growth arrest-specific 5 (GAS5) is a non-coding RNA regulated by mTOR, crucial for lymphocyte growth arrest.

Purpose of the Study:

  • To investigate the role of GAS5 in the efficacy of mTOR inhibitors (rapalogues) in mantle cell lymphoma.
  • To determine if downregulating GAS5 affects the anti-cancer activity of rapalogues in MCL.

Main Methods:

  • Mantle cell lymphoma cell lines were treated with rapalogues after endogenous GAS5 was downregulated using RNA interference.
  • Cell viability, DNA synthesis, and colony-forming ability were assessed to monitor the effects.

Main Results:

  • Downregulation of GAS5 significantly diminished the impact of rapalogues on cell viability.
  • Reduced GAS5 levels also impaired the effects of rapalogues on DNA synthesis and colony formation.

Conclusions:

  • GAS5 expression is critical for the cytotoxic and cytostatic effects of rapalogues in MCL.
  • Targeting the GAS5 pathway may enhance the therapeutic outcomes for mantle cell lymphoma.
Keywords:
ChemotherapyNon-Hodgkin lymphomaRapamycinmTORncRNA

More Related Videos

Author Spotlight: Developing Tools to Tune the Activity of Tyrosine Phosphatases06:56

Author Spotlight: Developing Tools to Tune the Activity of Tyrosine Phosphatases

Published on: September 6, 2024

856
A Semi-Quantitative Drug Affinity Responsive Target Stability DARTS assay for studying Rapamycin/mTOR interaction05:28

A Semi-Quantitative Drug Affinity Responsive Target Stability DARTS assay for studying Rapamycin/mTOR interaction

Published on: August 27, 2019

16.3K

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.6K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

1.5K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.0K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
5.1K
Small GTPases - Ras and Rho01:24

Small GTPases - Ras and Rho

Ras and Rho are small monomeric GTPases that act downstream of receptor tyrosine kinase (RTK) and regulate various cellular processes. These GTPases switch between active and inactive states by binding to guanine nucleotides.
Three regulatory proteins control their activity:
4.4K